MMP9 and prostate cancer: In addition, hsa-miR-15a is frequently downregulated in chronic lymphocytic leukemia, prostate cancer and non-small cell lung cancer (12–14), and the inhibition of hsa-miR-15a significantly increases the secreted matrix metalloproteinase-9 expression in neuroblastoma (15).